Esperion Announces Pricing of Public Offering of Common Stock ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a public offering price of $2.50 per share. In addition, Esperion has granted the underwrit...
Esperion Announces Proposed Public Offering of Common Stock ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced that it has commenced an underwritten public offering of shares of its common stock. Esperion also intends to grant the underwriters a 30-day option to purchase up to an additional fif...
Middlefield Banc Corp. Appoints Tim Oyster VP, Western Ohio Commercial Relationship Manager MIDDLEFIELD, Ohio, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ: MBCN) today announced that Tim Oyster has been appointed VP, Western Ohio Commercial Relationship Manager. In this role, Oyster will focus on delivering strategic advice to business clients in the Western Ohio Region, helping them improve cash flow, finance key assets, and mitigate risk. Mike Cheravitch, Chief Banking Officer, stated, “As we expand our commercial banking operations, Tim offers the expertise, lea...
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040 ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories, Inc. and its affiliate Dr. Reddy’s Laboratories Ltd. (together, Dr. Reddy’s Laboratories). This agreement resolves the patent litigation brought by Esperion against Dr. Reddy’s Laboratories in response to Dr. Redd...
American Assets Trust, Inc. Announces Third Quarter 2025 Earnings Release Date and Conference Call Information SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its third quarter 2025 earnings in a press release to be issued after the market closes on Tuesday, October 28, 2025. Senior management will hold a conference call for its third quarter 2025 earnings on Wednesday, October 29, 2025 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust,...
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® (bempedoic acid) tablets in Japan, has received approval from the Japanese Ministry of Health, Labour and Welfare to market NEXLETOL...
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias – Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence – – Guideline Recognition of ‘Strike Early and Strike Strong’ Approach with Early Combination Lipid-Lowering Therapy Affirms Continued Development of Company’s Oral Triple Combination Therapies in U.S. – ANN ARBOR, Mich., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today welcomed the inclusion of bempedoic acid as the only n...
Esperion to Participate in Upcoming September Investor Conferences ANN ARBOR, Mich., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of September, which can be found on our investor relations . Cantor Global Healthcare Conference in New York on September 3, 2025, at 9:45 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8, 2025, at 2:00 p.m. ET. Live webcasts can be accessed on the investor and media section of the Esperio...
A director at Arch Capital Group Ltd sold 10,000 shares at 94.146USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
UFP Technologies to Present and Host 1x1 Investor Meetings at the 16th Annual Midwest IDEAS Investor Conference on August 26th in Chicago, IL NEWBURYPORT, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (UFPT), today announced Mitch Rock, President, and Ron Lataille, Sr. VP and CFO, will present at the Midwest IDEAS Investor Conference on Tuesday, August 26, 2025, at The InterContinental in Chicago, IL. UFP’s presentation is scheduled to begin at 7:55 AM CT. The presentation is webcast and can be accessed through the conference host’s main website: and in the Investor Rel...
A director at Rayonier Advanced Materials Inc bought 53,533 shares at 4.709USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
Middlefield Banc Corp. Announces 2025 Third-Quarter Cash Dividend Payment MIDDLEFIELD, Ohio, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Middlefield Banc Corp. (NASDAQ: MBCN) today announced that its Board of Directors declared a quarterly cash dividend of $0.21 per common share. The 2025 third-quarter dividend is payable on September 12, 2025, to shareholders of record on August 29, 2025. About Middlefield Banc Corp. Middlefield Banc Corp., headquartered in Middlefield, Ohio, is the Bank holding Company of The Middlefield Banking Company, with total assets of $1.92 billion at June 30, 2025. The...
A director at Opko Health Inc bought 675,000 shares at 1.320USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such indivi...
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL® (bempedoic acid) Prior to 2040 – – First Quarter of Operating Income from Ongoing Business with Plans for Sustainable Profitability Starting in Q1 2026 – – Conference Call and Webcast Today at 8:00 a.m...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.